This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 343

Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data

By Adam Feuerstein

Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.

09:38AM 03/02/15

MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter

By Adam Feuerstein

Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.

08:15AM 03/02/15

Amgen Multiple Myeloma Drug Kyprolis Tops Rival in Study

By Adam Feuerstein

Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid to Onyx Pharmaceuticals.

10:25PM 03/01/15

Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

06:00AM 02/27/15

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

By Adam Feuerstein

To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.

11:47AM 02/25/15

Ampio Too Busy to Tell Investors Results of Eye Drug Study

By Adam Feuerstein

Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.

07:55AM 02/25/15

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results

By Adam Feuerstein

Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.

11:06AM 02/23/15

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

By Adam Feuerstein

The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.

03:47PM 02/20/15

Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger

By Adam Feuerstein

Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.

07:09AM 02/20/15

Biotech Stock Mailbag: MannKind, Mast Therapeutics, Bluebird

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

06:00AM 02/13/15

« Back
Page 1 of 343

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs